CG01 SIGNED
A novel gene therapy for epilepsy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CG01 project word cloud
Explore the words cloud of the CG01 project. It provides you a very rough idea of what is the project "CG01" about.
Project "CG01" data sheet
The following table provides information about the project.
| Coordinator |
COMBIGENE AB
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Project website | https://combigene.com/en/ |
| Total cost | 4˙801˙925 € |
| EC max contribution | 3˙361˙347 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2021-07-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | COMBIGENE AB | SE (LUND) | coordinator | 3˙361˙347.00 |
Map
Project objective
The aim of this project is to clinically validate CG01 as a novel gene therapy for the treatment of drug-resistant epilepsy patients. Epilepsy affects approximately 50 million people worldwide. 6 million Europeans are afflicted by the condition which annually costs around EUR 15 billion in France, Germany and the UK alone. Current standard of care entails anti-epileptic drug (AED) therapy. However, up to 30% of epileptics (20 million people worldwide) are unresponsive. Research to date has shown that adeno-associated virus (AAV) vector-mediated upregulation of the human neuropeptide Y (NPY) and its receptor Y2 inhibits epileptic seizures. This has inspired CG to develop CG01, a type of advanced therapy medicinal product based on the introduction of genes that encode human NPY and Y2 via the AAV vector into the brain cells of epileptic patients. AAV has already been shown as clinically safe and validated gene delivery system. The current project aims to translate promising findings in animal research into valid human data by bringing CG01 through a Phase I/II trial in drug resistant epilepsy patients. This will be the basis for further clinical development and commercialisation of the product. CombiGene’s strategic operations are currently aligned to establish CG01 as a novel epilepsy treatment. This innovation has the potential to revolutionize treatment for epileptics by delivering a treatment that may cure rather than just alleviate symptoms. Developing CG01 is integral to the company’s growth and this project is therefore essential in fulfilling the company’s long term vision.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CG01" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CG01" are provided by the European Opendata Portal: CORDIS opendata.